Disease · MONDO_0005198
vulvar intraepithelial neoplasia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. vulvar intraepithelial neoplasia. Diseases, record MONDO_0005198. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005198
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
VIN, intraepithelial neoplasia of the vulva, intraepithelial neoplasia of vulva, squamous vulvar intraepithelial neoplasia, vulva intraepithelial neoplasia, vulval intraepithelial neoplasia, vulvar intraepithelial tumor, vulvar intraepithelial tumour
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| IMIQUIMOD | CHEMBL1282 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OMIGANAN | CHEMBL1615933 | Protein | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRX-2 | CHEMBL4594479 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| BIZALIMOGENE RALAPLASMID | CHEMBL4297247 | Gene | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| ARTESUNATE | CHEMBL361497 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DECITABINE | CHEMBL1201129 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 1 | Toll-like receptor 7 agonist | Phase 3 | https://conductscience.org/library/genes/51284 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03267680 | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 | Phase 2 | 10 | 2025-04-13 | Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion | CYCLOPHOSPHAMIDE, IRX-2 | Its record names the disease | ClinicalTrials.gov |
| NCT01861535 | Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia | Phase 3 | 110 | Vulvar Intraepithelial Neoplasia | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov | |
| NCT05717621 | Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN) | Phase 1 | 29 | Vulvar Intraepithelial Neoplasia Grade 2, Vulvar Intraepithelial Neoplasia Grade 3 | DECITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03792516 | Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3) | Phase 1 | 15 | Vulvar Dysplasia, HPV-Related Vulvar Intraepithelial Neoplasia, Preinvasive Vulvar Disease, Vulva Intraepithelial Neoplasia, Vulvar Diseases | ARTESUNATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02596074 | Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN | Phase 2 | 12 | Usual Type Vulval Intraepithelial Neoplasia (uVIN) | OMIGANAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00941811 | Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment | Phase 2 | 5 | HPV | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (IRX-2) vs Arm II (Placebo): deaths from any cause | 0 of 7 | 0 of 3 | 10 | NCT03267680 | Trial comparisons |
| Arm I (IRX-2) vs Arm II (Placebo): serious adverse events | 0 of 7 | 0 of 3 | 10 | NCT03267680 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005198
GET https://conductscience.org/api/diseases/v1/MONDO_0005198/drugs